Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

FORWARD PHARMA A/S

(FWP)
Delayed Nasdaq  -  03:40 2022-12-07 pm EST
2.920 USD   -8.46%
12/06Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review
AQ
11/30European Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/21Forward Pharma A/s : Amended and Restated Articles of Association, dated November 9, 2022 - Form 6-K
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
Business Summary
Logo Forward Pharma A/S
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.

Number of employees : 4 people.
Managers
Name Title Age Since
Claus Bo Svendsen CEO & Principal Financial Officer 45 -
Thomas Carbone Principal Accounting Officer & VP-Finance 64 2014
Members of the board
Name Title Age Since
Florian Schönharting Director 53 2005
Grant Hellier Lawrence Independent Director 60 2015
Duncan Charles Mcnaught Moore, Dr. Independent Director 61 2016
Torsten Rüdiger Goesch, Dr. Director 62 2006
Jakob Mosegaard Larsen Director 49 2015
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 98,264,429 6,729,537 6.8% 0 0.0% 6.8%
Shareholders
NameEquities%
BVF Partners LP 513,791 7.25%
The Baupost Group LLC 406,857 5.74%
Newtyn Management LLC 340,599 4.80%
Assured Investment Management LLC 180,890 2.55%
Morgan Stanley & Co. LLC 163,282 2.30%
Mason Capital Management LLC 150,217 2.12%
RA Capital Management LP 138,657 1.96%
OrbiMed Advisors Private Equity 114,000 1.61%
Senzar Asset Management LLC 93,214 1.31%
Cormorant Asset Management LP 84,168 1.19%
Company contact information
Forward Pharma A/S
Østergade 24A
1st Floor
Copenhagen, Capital Region 1100

Phone : +45.33.44.42.42
Web : http://www.forward-pharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Forward Pharma A/S